Italia markets close in 3 hours 25 minutes

Hansa Biopharma AB (publ) (0RC7.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
104,50+11,63 (+12,52%)
In data: 05:53PM BST. Mercato aperto.

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Settore/i
Settore
Impiegati a tempo pieno166

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Søren Tulstrup M.ScPresident & CEO16,12MN/D1965
Mr. C. Evan BallantyneChief Financial OfficerN/DN/D1960
Dr. Christian KjellmanSenior VP & COON/DN/D1967
Dr. Hitto Kaufmann Ph.D.Chief Scientific OfficerN/DN/D1971
Ms. Eva-Maria JoedVice President of Finance & AdministrationN/DN/D1969
Mr. Klaus SindahlVP & Head of Investor RelationsN/DN/DN/D
Ms. Anne Säfström LannerSenior VP & Chief Human Resources OfficerN/DN/D1969
Mr. Emanuel BjörneVP & Head of Business DevelopmentN/DN/D1973
Dr. Lena WinstedtHead of ScienceN/DN/D1969
Ms. Vincenza Nigro M.B.A.VP & Head of Medical AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 giugno 2024 è 1. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.